EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave", or the "Company")
announced today that it has signed a Testing Agreement (the "Agreement") with a
Tier 1 pharmaceutical company (the "Tier 1") that is in the top five globally
for Research and Development spending. The Agreement allows the Tier 1 to
exclusively test EnWave's Radiant Energy Vacuum ("REV(TM)") technology for the
dehydration of monoclonal antibodies ("mAbs"). The testing period is expected to
begin in late March 2014. 


Prior to signing this Agreement, EnWave received positive results in 2011 from a
12 month study comparing the Company's REV(R) dehydration technology against the
standard industrial drying method, freeze drying, in the dehydration of pure
samples of a FITC-conjugated and unconjugated animal-derived mAbs. The results
showed that the drying methods were equivalent in terms of the structural
changes incurred by the antibodies both immediately post-dehydration, and over
the course of the 12 month shelf-life period, but that the samples dried using
REV(R) were dehydrated in considerably less time than required for freeze
drying. This was a significant test result as mAbs are much more sensitive and
therefore prone to degradation during dehydration.


mAbs are produced by a single clone of cells grown in culture, that is both pure
and specific and is capable of proliferating indefinitely to produce unlimited
quantities of identical antibodies. Beyond basic research, in recent years,
therapeutic mAbs have become an increasingly important component of
pharmacotherapy and have made a significant impact on the drug discovery and
development process. 


Although antibodies are not considered live organisms, dehydration can cause
them to become inactive, and therefore ineffective for use in pharmaceutical and
other products, by changing or "denaturing" their outer protein structure.


"We have proven that REV(TM) technology can efficiently dehydrate monoclonal
antibodies while preserving their efficacy," stated Dr. Tim Durance, Chairman &
Co-CEO of EnWave Corporation. "This Agreement will provide the opportunity to
exhibit the value proposition to this leading Tier 1 pharmaceutical partner."


About EnWave 

EnWave Corporation is a Vancouver-based industrial technology company developing
commercial applications for its proprietary Radiant Energy Vacuum (REV(TM))
dehydration technology. EnWave aims to sign royalty-bearing commercial licenses
with leading food and pharmaceutical companies for the use of its revolutionary
technology. Thus far the Company has signed commercial licenses with Bonduelle,
a global leader in the production of vegetables, for the processing of
dehydrofrozen vegetables; Hormel Foods Corporation, a major processed meat
manufacturer, for the production of healthy dried meat products; Milne Fruit
Product, EnWave's first major licensee, for the production of several dehydrated
fruit and vegetable products in the whole, fragmented and powdered form; a
leading North American enzyme company, to dehydrate a series of food-related
enzymes for their Tier 1 clients; and Napa Mountain Spice Company, to dry
high-quality California bay leaves. In addition to these licenses, EnWave has
formed a Limited Liability Partnership with Lucid Capital Management to develop,
manufacture, market and sell all-natural cheese snack products in the United
States under the Moon Cheese(R) brand. 


Also, EnWave has entered into a wide range of research and collaboration
agreements with an expanding list of multinational companies, including Nestle,
Kellogg's, Grupo Bimbo, Grimmway Farms, Ocean Spray Cranberries, Cherry Central,
Sun-Maid Growers, Gay Lea Foods, R.J. Reynolds and Merck. EnWave is introducing
REV(TM) as a new dehydration standard in the food and biological material
sectors: potentially faster and cheaper than freeze drying, with better end
product quality than air drying or spray drying.


EnWave currently has six REV(TM) platforms: commercial-scale nutraREV(R) and
MIVAP(R) are used in the food industry to dry fruits, vegetables, meat, herbs
and seafood quickly and at low-cost, while maintaining high levels of nutrition,
taste, texture and colour. The Company is also developing powderREV(R) for bulk
dehydration of food cultures, probiotics and fine biochemicals such as enzymes;
quantaREV(TM) for continuous, high-volume low-temperature drying of pastes,
gels, liquids, or particulates; and bioREV(TM) and freezeREV(TM) as new methods
to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies.
More information about EnWave is available at www.enwave.net. 


EnWave Corporation

Dr. Tim Durance, Chairman & Co-CEO 

Safe Harbour for Forward-Looking Information Statements: This press release may
contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's strategy
for growth, product development, market position, expected expenditures, and the
expected synergies following the closing are forward-looking statements. All
third party references to market information in this release are not guaranteed
to be accurate as the Company did not conduct the original primary research.
These statements are not a guarantee of future performance and involve a number
of risks, uncertainties and assumptions. Although the Company has attempted to
identify important factors that could cause actual results to differ materially,
there may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ materially from
those anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
EnWave Corporation
Mr. John McNicol
President & Co-CEO
(604) 601-8524
john.mcnicol@enwave.net


EnWave Corporation
Mr. Brent Charleton
Vice President, Corporate Affairs
(778) 378-9616
bcharleton@enwave.net
www.enwave.net
EnWave (TSXV:ENW)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more EnWave Charts.
EnWave (TSXV:ENW)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more EnWave Charts.